Seelos's Amyotrophic Lateral Sclerosis Candidate, SLS-005 An Orphan Drug In Europe
- Seelos Therapeutics Inc's (NASDAQ: SEEL) Trehalose (SLS-005) has received Orphan Drug Designation for amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).
- Under the orphan designation, Seelos stands to benefit from several incentives such as protocol assistance, reduced regulatory fees, and market exclusivity.
- Price Action: SEEL shares are up 2.9% at $3.17 during the premarket session on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: BriefsBiotech News Penny Stocks Health Care Small Cap FDA General
